Oncology Medical News about head and neck cancer, sunitinib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer
Cancer Chemotherapy and Pharmacology, 08/12/09

Fountzilas G et al. - In a study to evaluate the activity and safety of sunitinib in pts with recurrent and/or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN), it was shown that sunitinib monotherapy was not proven active in RM-SCCHN, and no further development of the drug in this indication is warranted.

Methods

17 pts were treated with sunitinib 50 mg per day administrated in 4-wk cycles followed by a rest period of 2 wks.
Sunitinib and SU012662 plasma levels were determined based on a validated liquid chromatography-tandem mass spectrometry method and pharmacokinetic data were fitted in a non-compartmental analysis.

Results

28 6-wk cycles of treatment with sunitinib were administered (median, 2 cycles).
Only 3 pts demonstrated stabilization of the disease; thus, the study had to be terminated prematurely due to futility.
Grade 3 toxicities, apart from fatigue, were infrequent.
Other frequently reported side effects were skin discoloration, neutropenia, and thrombocytopenia.
10 various bleeding complications were reported in 7 pts.
Mean maximum concentrations (C max) were reached during the first day of treatment for sunitinib at 38.98 (±22.66) ng/ml and for SU012662 at 11.12 (±24.57) ng/ml.
SU012662 has a longer half-life and a larger volume of distribution than the parent drug sunitinib.
None of the biological markers tested was of any prognostic value.

<< Previous
A phase I dose escalation study of a pharmacobiologically based...

Next >>
Gemcitabine and oxaliplatin in patients with unresectable biliary...